---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336715"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2026-08-06T11:10:15+00:00"
generated_at: "2026-08-06T11:15:42.842730+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Q2 net loss $109.9M; apitegromab BLA on track for FDA decision by Sept 30, 2026

## Summary
- Net loss of $109.9M ($0.84 per share) vs $110.0M ($0.98) in Q2 2025; no revenue recorded.
- Cash, equivalents, and marketable securities of $492.1M as of June 30, 2026, including $62.8M net from ATM.
- Apitegromab BLA for SMA under FDA review with two fill-finish facilities; PDUFA date Sept 30, 2026; ample supply for launch.
- Initiated Phase 2 FORGE trial in FSHD (approx 60 patients, primary endpoint LMV at 12 months).
- Engaging with EMA on apitegromab MAA; FDA inspection classification of Catalent Indiana pending.

## SEC filing metadata
- accession: 0001193125-26-336715
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2026-08-06T11:10:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/0001193125-26-336715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336715
- JSON: https://secwatch.observer/filing/0001193125-26-336715.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.